A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Trial Profile

A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Paraganglioma; Phaeochromocytoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Molecular Insight Pharmaceuticals; Progenics Pharmaceuticals
  • Most Recent Events

    • 22 Mar 2018 According to a Progenics Pharmaceuticals media release, U.S. Food and Drug Administration (FDA) Agency has extended its review of the New Drug Application for AZEDRA by three months to July 30, 2018 due to submission of additional Chemistry, Manufacturing, and Controls (CMC) information by Progenics and not due to the efficacy or safety data of AZEDRA.
    • 19 Mar 2018 According to a Progenics Pharmaceuticals media release, data from this trial was presented at the Endocrine Society (ENDO) Annual Meeting.
    • 19 Mar 2018 Results presented in the Progenics Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top